Skip to content

The effect of mirabegron on female sexual function

The effect of mirabegron, used for overactive bladder treatment, on female sexual function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17199301
Enrollment
70
Registered
2017-10-20
Start date
2016-01-20
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder (OAB), female sexual function Urological and Genital Diseases Overactive bladder (OAB), female sexual function

Interventions

Participants are allocated to one of two groups. Group A, which is defined as a control group, consists of at least 35 women. None of these females with OAB wishes to receive any therapy. In Group B,

Sponsors

Elpis Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women over the age of 18 being in a sexually active relationship suffering from OAB for a minimal period of 3 months 2. None of the latter women received previously treatment for OAB 3. Willing of women to comply with the protocol and the capability to complete the voiding diaries and the questionnaires without assistance

Exclusion criteria

Exclusion criteria: 1. Clinically significant stress urinary incontinence 2. Neurogenic bladder and urinary retention or are at risk for these conditions 3. Women with a history of pelvic muscle training programs will be excluded because it is accepted that pelvic floor muscle exercises improve female sexual function 4. Women who state that they are not sexually active will be excluded from further analysis 5. Women who consider that there is no need for long-term treatment for OAB or are afraid of regimen’s adverse effects are included in control group

Design outcomes

Primary

MeasureTime frame
Female sexual function is measured using the FSFI score at baseline and 12 months.

Secondary

MeasureTime frame
1. Voiding frequency is measured using the 3 day micturition diary at baseline and after three months 2. Nocturia is measured using the 3 day micturition diary at baseline and after three months 3. Urgency episodes measured using the 3 day micturition diary at baseline and after three months 4. Incontinent episodes is measured using the 3 day micturition diary at baseline and after three months 5. Number of incontinence pads is meaured using the 3 day micturition diary at baseline and after three months 6. Voided volume is measured using the 3 day micturition diary at baseline and after three months

Countries

Greece

Contacts

Public ContactAthanasios Zachariou

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 6, 2026